Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

By A. Shuldiner, J. O’Connell, K. Bliden, A. Gandhi, K. Ryan, R. Horenstein, Coleen Damcott, Ruth E. Pakyz, U. Tantry, Q. Gibson and 7 more. Journal of the American Medical Association (JAMA), 2009

1,579 citations recorded by the source corpus.

Subfields: Biochemistry, Cardiology and Cardiovascular Medicine, Hematology

View Paper: https://www.semanticscholar.org/paper/e46f5147b7f597bbb7567e4686128e830a98e6fa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jose Luis Zamorano
2. Stephan Windecker

Citations in the corpus

• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, background): “Moreover, only 6–12% of the variability in on-clopidogrel platelet reactivity can be explained by the differences in genotype [68, 69].”